<DOC>
	<DOC>NCT01538992</DOC>
	<brief_summary>Sympathetic system has important role occurrence of symptoms in heart failure. Renal denervation that is ablated some of sympathetic nerves is affected pathology of heart failure. This interventional therapy improves symptoms and life quality.</brief_summary>
	<brief_title>Renal Denervation in Patients With Advanced Heart Failure</brief_title>
	<detailed_description>Primary Outcome Measures: • Safety of Renal Denervation in Heart Failure patients as measured by Adverse Events Secondary Outcome Measures: • Ventricular function,NYHA functional Class, 6 min walking test, biochemical test and Renal function as measured by Glomerular Filtration Rate (GFR) Eligibility Patients population: Volunteers, NYHA Class III-IV heart failure patients. Ages Eligible for Study: 18 Years to 85 Years Genders Eligible for Study: Both Accepts Healthy Volunteers: No</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Heart Failure patients NYHA Class III or IV Left Ventricular Ejection Function &lt; 35% GFR &gt; 45 mL/min/1.73m2 Optimal stable medical therapy Do not eligible renal artery anatomy for treatment as determined by Angiography, and History of prior renal artery intervention Single functioning kidney. Myocardial Infarction, unstable angina pectoris or cerebrovascular Accident within 3 months Systolic BP &lt; 110mmHG Hospitalisation because of heart failure in last 3 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>renal denervation</keyword>
	<keyword>heart failure</keyword>
</DOC>